JP5658152B2 - 非細胞毒性融合タンパク質 - Google Patents

非細胞毒性融合タンパク質 Download PDF

Info

Publication number
JP5658152B2
JP5658152B2 JP2011523457A JP2011523457A JP5658152B2 JP 5658152 B2 JP5658152 B2 JP 5658152B2 JP 2011523457 A JP2011523457 A JP 2011523457A JP 2011523457 A JP2011523457 A JP 2011523457A JP 5658152 B2 JP5658152 B2 JP 5658152B2
Authority
JP
Japan
Prior art keywords
egf
amino acid
seq
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011523457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500018A (ja
JP2012500018A5 (https=
Inventor
コシンズ，エイミー
バーチ−マチン，イアン
スタンクーム，パトリック
チャドック，ジョン
ビアード，マシュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Bioinnovation Ltd
Original Assignee
Ipsen Bioinnovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Bioinnovation Ltd filed Critical Ipsen Bioinnovation Ltd
Publication of JP2012500018A publication Critical patent/JP2012500018A/ja
Publication of JP2012500018A5 publication Critical patent/JP2012500018A5/ja
Application granted granted Critical
Publication of JP5658152B2 publication Critical patent/JP5658152B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2011523457A 2008-08-21 2009-08-19 非細胞毒性融合タンパク質 Expired - Fee Related JP5658152B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0815264.7A GB0815264D0 (en) 2008-08-21 2008-08-21 Non-cytotoxic proteins
GB0815264.7 2008-08-21
PCT/GB2009/051036 WO2010020811A1 (en) 2008-08-21 2009-08-19 Non-cytotoxic fusion proteins comprising egf muteins

Publications (3)

Publication Number Publication Date
JP2012500018A JP2012500018A (ja) 2012-01-05
JP2012500018A5 JP2012500018A5 (https=) 2014-08-07
JP5658152B2 true JP5658152B2 (ja) 2015-01-21

Family

ID=39812369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011523457A Expired - Fee Related JP5658152B2 (ja) 2008-08-21 2009-08-19 非細胞毒性融合タンパク質

Country Status (9)

Country Link
US (1) US8614069B2 (https=)
EP (1) EP2326665B1 (https=)
JP (1) JP5658152B2 (https=)
DK (1) DK2326665T3 (https=)
ES (1) ES2436816T3 (https=)
GB (1) GB0815264D0 (https=)
PL (1) PL2326665T3 (https=)
PT (1) PT2326665E (https=)
WO (1) WO2010020811A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8790897B2 (en) * 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
AU2011323832B2 (en) * 2010-10-25 2016-06-02 Niiki Pharma Inc. Method of treating neuroendocrine tumors
KR101519118B1 (ko) * 2013-07-23 2015-05-12 (주)피앤피바이오팜 고안정성 상피세포 성장인자 변이체
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
HK1250011A1 (zh) * 2015-03-31 2018-11-23 Sorriso Pharmaceuticals, Inc. 具有蛋白酶可切割接头的肽构建体
DK3277719T3 (da) 2015-03-31 2022-05-02 Sorriso Pharmaceuticals Inc Polypeptider
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
US11241480B2 (en) * 2017-01-26 2022-02-08 Washington University Methods for modulation of dietary and microbial exposure with compositions comprising an EGFR ligand
UA128185C2 (uk) 2018-01-29 2024-05-01 Іпсен Біофарм Лімітед Ботулінічний нейротоксин, який розщеплює ненейронний snare
GB201815817D0 (en) * 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) * 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
WO2020219599A1 (en) * 2019-04-23 2020-10-29 Aurora Oncology Compositions and methods for treatment of distentable tissues
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
WO2020254827A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides
JP7680377B2 (ja) 2019-06-21 2025-05-20 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
WO2024249812A2 (en) * 2023-06-01 2024-12-05 Blaze Bioscience, Inc. Egf variants and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003A (en) * 1851-03-25 Improvement in scythe-tastenings
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US8790897B2 (en) * 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
US20080038274A1 (en) * 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
US7037504B2 (en) 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
EP1479693A4 (en) 2002-02-05 2005-07-27 Japan Science & Tech Agency EGF / EGFR COMPLEX
WO2007109673A2 (en) * 2006-03-20 2007-09-27 Stanford University Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
GB0725321D0 (en) 2007-12-31 2008-02-06 Syntaxin Ltd Delivery vehicles

Also Published As

Publication number Publication date
ES2436816T3 (es) 2014-01-07
PL2326665T3 (pl) 2014-03-31
US20110177056A1 (en) 2011-07-21
EP2326665B1 (en) 2013-10-09
JP2012500018A (ja) 2012-01-05
GB0815264D0 (en) 2008-09-24
EP2326665A1 (en) 2011-06-01
WO2010020811A1 (en) 2010-02-25
PT2326665E (pt) 2013-12-23
US8614069B2 (en) 2013-12-24
DK2326665T3 (da) 2013-11-25

Similar Documents

Publication Publication Date Title
JP5658152B2 (ja) 非細胞毒性融合タンパク質
JP2012500018A5 (https=)
US10744190B2 (en) Method for suppressing spasmodic torticollis
CA2727082C (en) Fusion proteins for use in suppression of acromegaly
JP6050330B2 (ja) 治療用融合タンパク質
EP2310029B1 (en) Fusion proteins for use in the treatment of cancer
US8796216B2 (en) Suppression of neuroendocrine diseases
JP2012518403A5 (https=)
US20150353908A1 (en) Therapeutics for suppressing osteoporosis
JP2020039349A (ja) かゆみの抑制
JP2025532862A (ja) 活性化外因性プロテアーゼ切断部位を含むクロストリジウム神経毒
JP2024510786A (ja) 外来性の活性化ループを含むクロストリジウム神経毒素
AU2014200449B2 (en) Suppression of neuroendocrine diseases
JP2025534299A (ja) 活性化エンドソームプロテアーゼ切断部位を含むクロストリジウム神経毒
HK40020225A (en) Suppression of neuroendocrine diseases
HK1154512A (en) Fusion proteins for use in the treatment of acromegaly
HK1154512B (en) Fusion proteins for use in the treatment of acromegaly
HK1190946A (en) Fusion proteins for use in the treatment of acromegaly

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140522

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140529

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141009

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141127

R150 Certificate of patent or registration of utility model

Ref document number: 5658152

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees